CLSD Clearside Biomedical Inc
4,970
$1.23
$0.02
(1.60%)
| Watchers | 4,970 |
| 52-Wk Low | $0.6501 |
| 52-Wk High | $2.12 |
| Market Cap | $91.92M |
| Volume | 110,213.00 |
| 52-Wk High | $2.12 |
| 52-Wk Low | $0.6501 |
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobe Newswire • about 1 month ago
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Share to Feed
Clearside Biomedical, Inc. (NASDAQ:CLSD Free Report) Analysts at Wedbush issued their Q1 2024 EPS estimates for shares of Clearside Biomedical in a research note issued on Wednesday...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development
Victor Chong, M.D., MBA
Victor...
Wedbush restated their outperform rating on shares of Clearside Biomedical (NASDAQ:CLSD Free Report) in a report released on Wednesday morning, RTT News reports. The firm currently has a...
Related Stocks: NAS:CLSD...
Licensing Deals Propel Revenue as Company Advances Clinical TrialsRelated Stocks: CLSD...
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector - - Strengthened...
Clearside Biomedical, Inc. (NASDAQ:CLSD Get Free Report) has been given an average recommendation of Buy by the four analysts that are presently covering the firm, Marketbeat...